Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MindBio Therapeutics Corp C.MBIO

Healthcare Biotechnology
MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its... see more

Recent & Breaking News (CSE:MBIO)

MindBio Therapeutics CEO To Present at Emerging Equities Life Sciences VIP Event and Showcase MindBio's Research at Upcoming MAPS Psychedelics Science Conference in Colorado

Accesswire June 6, 2023

MindBio Therapeutics CEO Demonstrates how 1 Million Microdoses of LSD can Potentially be Used to Treat Depression at Scale

Accesswire May 30, 2023

Psychedelics stock moving forward with pioneering LSD clinical trial

Trevor Abes  May 23, 2023

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Accesswire May 23, 2023

MindBio Therapeutics Chief Executive Officer Issues Letter to Shareholders Discussing the Company's Growth Plans

Accesswire May 16, 2023

MindBio Therapeutics Phase 2 Clinical Trial Has Received Ethics Approval for World First Take-Home LSD-Microdosing Trials in Cancer Patients Experiencing Emotional Distress

Accesswire May 11, 2023

MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants

Accesswire May 9, 2023

MindBio Therapeutics - Now Trading on the CSE

Research May 5, 2023

MindBio Therapeutics (CSE:MBIO) begins trading on the CSE

Trevor Abes  May 5, 2023

MindBio Therapeutics Corp (CSE:MBIO) Lists its Common Shares on the Canadian Securities Exchange

Accesswire May 5, 2023